Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A process to induce an effector cell mediated immune response against tumor cells in a cancer patient, said method comprising

administering, to a cancer patient, a non-infectious, biologically generated virus particle with a cellular membrane from a host cell, said membrane comprising

an MHC molecule that presents ~~one or more~~ at least one exogenous tumor specific antigen ~~antigens~~, and

a co-stimulatory molecule,

wherein said non-infectious virus particle is an inactivated intact virus particle that was infectious, and

wherein said host cell was modified to express the exogenous tumor specific antigen, and

wherein said administering is of an amount effective to induce an effector cell mediated immune response against tumor cells in said patient.

2. (Previously presented) The process of claim 1 wherein said immune response is mediated by T cells.

3. (Previously presented) The process of claim 1 wherein said non-infectious particle is released from a homologous tumor cell from the patient.

4. (Previously presented) The process of claim 1 wherein said non-infectious particle is released from a matched major histocompatibility complex containing tumor cell.

5. (Previously presented) The process of claim 1 wherein said non-infectious particle is released from a non-homologous tumor cell line containing one or more matched human leukocyte antigens.

6-15. (canceled)

16. (Previously presented) The process of claim 1 wherein said immune response reduces the number of tumor cells in said patient and thereby treats cancer in said patient.

17. (Currently amended) The process of claim 1 wherein said host cell expresses ~~one or more~~ the exogenous tumor specific antigen ~~antigens~~ on the cell's cell membrane and said particle has a membrane that further comprises the ~~one or more antigens~~ exogenous tumor specific antigen.

18. (Previously presented) The process of claim 1 wherein said particle mimics a dendritic cell.

19-20. (canceled)

21. (Previously presented) The process of claim 1 wherein said host cell is a non-tumor cell.

22. (canceled)

23. (Previously presented) The process of claim 1 wherein said co-stimulatory molecule is a B7 family molecule.

24-26. (canceled)

27. (New) The process of claim 1, wherein said co-stimulatory molecule is selected from CD40, CD40 ligand, CD30, CD30 ligand, 4-IBB receptor, 4-IBB ligand, CD27, FAS receptor, FAS ligand, TRAIL receptor, and TRAIL ligand.

28. (New) The process of claim 1, wherein said co-stimulatory molecule is a cytokine.

29. (New) The process of claim 28, wherein said cytokine is selected from an interleukin, a colony stimulatory factor, and a tumor necrosis factor.

30. (New) The process of claim 29, wherein said interleukin is selected from IL-2, IL-12, IL-15, and IL-23.

31. (New) The process of claim 29, wherein said colony stimulatory factor is GM-CSF.

32. (New) The process of claim 29, wherein said tumor necrosis factor is TNF-alpha.

33. (New) The process of claim 1, wherein said co-stimulatory molecule is an antibody.

34. (New) The process of claim 33, wherein said antibody is selected from anti-CD3, anti-CD20, anti-CD28, and anti-CTLA4.

35. (New) The process of claim 1, wherein after said administering, the exogenous tumor specific antigen is transferred to an antigen-presenting cell in said cancer

patient, and the antigen-presenting cell induces the effector cell mediated immune response against tumor cells in said cancer patient.

36. (New) The process of claim 1, wherein the exogenous tumor specific antigen is a tumor-specific transplantation antigen (TSTA).